Processa Pharmaceuticals (PCSA) Shares Outstanding: History & Chart

Processa Pharmaceuticals, Inc.(PCSA)

Biotechnology · Vero Beach, FL

$1.49-0.00 (-0.34%)

Delayed quote: Oct 6, 2026, 2:48 PM EDT

About Processa Pharmaceuticals, Inc.

Processa Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development stage, committed to identifying and progressing therapeutic agents for patients with critical unmet medical requirements throughout the United States. The company's leading investigational drug, PCS499, is an oral tablet presently undergoing Phase 2B clinical assessment. It aims to treat both ulcerative and non-ulcerative manifestations of necrobiosis lipoidica, a chronic and disfiguring dermatological condition. Processa's portfolio also features PCS12852, a unique selective 5-hydroxytryptamine 4 (5-HT4) receptor agonist. This compound is currently in Phase 2A clinical trials for its potential application in managing gastroparesis, chronic constipation, constipation-predominant irritable bowel syndrome, and functional dyspepsia. Furthermore, the firm is advancing PCS3117, a cytosine analog, which has reached Phase 2B clinical trials for its use in pancreatic cancer and non-small cell lung cancer. Another candidate, PCS6422, an oral, potent, selective, and irreversible inhibitor of dihydropyrimidine dehydrogenase, is progressing through Phase 1B clinical trials for metastatic colorectal and breast cancers. In addition, Processa is developing PCS11T, an analog derived from the drugs SN38 and irinotecan, intended for the treatment of diverse cancer types. The company was founded in 2011 and maintains its corporate headquarters in Hanover, Maryland.

Vero Beach, FL

12 employees

www.processapharmaceuticals.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: George K. Ng

View full financials

Latest FMP share-count observation

Shares outstanding

2,768,030

Float shares

2,337,883

Source: FMP shares-float. FMP feed updated 2026-10-05 16:26:40 (timezone not supplied). The feed does not specify the effective date of this share count.

Shares outstanding measure the share count in the provider observation. Basic and diluted weighted averages below are EPS calculation inputs. Differences between these counts do not measure new issuance or buybacks.

Weighted-average shares by quarterly statement

FMP normalized EPS denominators, labeled by statement period end. These are weighted averages, not current shares outstanding. The provider's period duration may include year-to-date values.

Statement period	Period end	Weighted average basic shares	Weighted average diluted shares
Q2 FY2026	2026-06-30	2,750,742	2,750,742
Q1 FY2026	2026-03-31	2,623,143	2,623,143
Q4 FY2025	2025-12-31	2,571,914	2,571,914
Q3 FY2025	2025-09-30	1,901,021	1,901,021
Q2 FY2025	2025-06-30	622,772	622,772
Q1 FY2025	2025-03-31	381,072	381,072
Q4 FY2024	2024-12-31	147,870	147,870
Q3 FY2024	2024-09-30	131,040	131,040
Q2 FY2024	2024-06-30	119,331

Weighted-average shares by annual statement

FMP normalized EPS denominators, labeled by statement period end. These are weighted averages, not current shares outstanding. The provider's period duration may include year-to-date values.

Statement period	Period end	Weighted average basic shares	Weighted average diluted shares
2025	2025-12-31	1,309,271	1,309,271
2024	2024-12-31	122,396	122,396
2023	2023-12-31	52,463	52,463
2022	2022-12-31	32,219	32,219
2021	2021-12-31	30,639	30,639
2020	2020-12-31	14,999	14,999
2019	2019-12-31	11,051	11,051
2018	2018-12-31	10,664	10,664
2017	2017-12-31	9,313	9,313

Shares Outstanding: 2,768,030

Latest FMP share-count observation

PCSA Weighted Average Basic Shares

PCSA Weighted Average Diluted Shares

Weighted-average shares by quarterly statement

Weighted-average shares by annual statement